Potentially practice-changing data was presented at 2018 ASH Annual Meeting and Exposition (December 1–4, 2018; CA, USA), read our round-up to discover the key studies. Highlights include the CASSINI and MAIA trial data,
Browsing: Disease Area > Hematologic
A personalized prediction scheme for certain chronic blood cancers has been developed, based on new disease classifications.
Adult cancer patients in England will receive the new game-changing CAR-T therapy Yescarta® under the first negotiated deal of its kind struck in Europe.
The ground breaking CAR-T therapy – Kymriah® – is set to become the first personalized cancer therapy available on the NHS.
Yescarta®, a novel personalized CAR T cell therapy has been approved for use in Europe by the EMA but has received a draft negative guidance from NICE.
The largest ever study of its kind has become the first to definitively show an increased risk of blood cancers in relatives of patients.
A multi-disciplinary team of researchers have developed comprehensive CAR T-cell therapy pediatric guidelines.
The FDA has approved TIBSOVO – the first oral, targeted therapy for relapsed/ refractory acute myeloid leukemia (R/R AML) adults patients and an IDH1 mutation.